Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies-Reference-Cited by-同舟云学术

Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies

Published:2013-08 Issue:8 Volume:8 Page:e75-e78
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Kobayashi Yoshihisa,Sakao Yukinori,Ito Simon,Park Jangchul,Kuroda Hiroaki,Sakakura Noriaki,Usami Noriyasu,Mitsudomi Tetsuya,Yatabe Yasushi

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference6 articles.

1. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N Engl J Med,2010

2. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors;Sequist;Sci Transl Med,2011

3. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers;Katayama;Sci Transl Med,2012

4. Epithelial-mesenchymal transitions in tumour progression;Thiery;Nat Rev Cancer,2002

5. Palliative chemotherapy for pulmonary pleomorphic carcinoma;Bae;Lung Cancer,2007

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sarcomatous transformation in metastatic EGFR-mutant lung adenocarcinoma after TKI treatment, a case report;Asian Journal of Surgery;2024-06

2. Histologic transformation of non‐small‐cell lung cancer in response to tyrosine kinase inhibitors: Current knowledge of genetic changes and molecular mechanisms;Cancer Science;2024-05-27

3. EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation;Journal of Experimental Medicine;2024-01-29

4. From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC);Diagnostics;2023-12-25

5. Tumor plasticity and therapeutic resistance in oncogene-addicted non-small cell lung cancer: from preclinical observations to clinical implications;Critical Reviews in Oncology/Hematology;2023-04